NanoBio Corp. announced the company will present new data at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy meeting showing the safety and effectiveness of a vaccine for the prevention of respiratory syncytial virus, enhanced by the company’s nanoemulsion technology.
NanoBio Corp. Tuesday said that it is presenting new data demonstrating positive pre-clinical results for its intramuscular respiratory syncytial virus vaccine at the National Foundation for Infectious Diseases 16th Annual Conference on Vaccine Research.
NanoBio Corp. announced Wednesday the closing of an $11 million Series C financing, including full participation from its existing investor syndicate.
NanoBio Corp. said it will present data from two separate preclinical studies at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy meeting this week in San Francisco.
Nanobio Corp. Thursday announced a preclinical collaboration with a subsidiary of Merck & Co. Inc. focused on the development of a vaccine for Respiratory Syncytial Virus (RSV).
NanoBio Corp. announced Wednesday that data from recent animal studies of its NanoStat-based intranasal respiratory syncytial virus vaccine have shown strong immunity effects, paving the way for more studies of the nanoparticle-based technology.
Ann Arbor-based NanoBio Corp. last week announced a licensing agreement with the National Institutes of Health that represents a significant step forward in developing the first vaccine to protect against respiratory syncytial virus (RSV) infections.
Ann Arbor-based NanoBio Corporation announced Tuesday that it has received a $6 million grant from the Bill & Melinda Gates Foundation to support development of an intranasal vaccine for Respiratory Syncytial Virus.